Last reviewed: June 22, 2026
Last updated: June 22, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Mounjaro (tirzepatide) and Ozempic (semaglutide) dominate weight loss conversations, yet they work through fundamentally different pathways in your body. Tirzepatide activates two hormone receptors—GLP-1 and GIP—while semaglutide targets GLP-1 alone. Clinical trials show tirzepatide produced greater weight reduction in head-to-head comparisons, but individual response varies based on your unique genetic and metabolic makeup.
How Tirzepatide and Semaglutide Work Differently
Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone that signals fullness, slows stomach emptying, and helps regulate blood sugar. This single-receptor activation has proven effective for millions seeking sustainable weight loss over the past decade.
Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously. This dual-action approach amplifies appetite suppression and metabolic effects, offering a distinct pharmacological strategy that some patients find more effective for their individual physiology.
The key difference: semaglutide is a monotherapy targeting one pathway, while tirzepatide engages two related but separate metabolic mechanisms. Neither approach is universally superior—response depends on your genetic predisposition to each receptor and peptide system.
Clinical Trial Results: Weight Loss Outcomes Compared
The SURMOUNT trial series demonstrated that tirzepatide produced average weight losses ranging from 21–22% of body weight at the highest dose, compared to semaglutide's average of 14–17% in comparable trials. However, these figures reflect average outcomes across diverse populations; individual results span a broad spectrum.
Semaglutide's longer clinical history—approved for weight loss in 2021—includes robust real-world evidence across millions of doses. Tirzepatide, approved for weight loss in 2023, is building its long-term safety database rapidly as more patients access the medication.
Both medications significantly improve cardiovascular risk factors, blood sugar control, and metabolic health markers. The 'better' choice depends on your baseline health status, genetic factors, tolerance for side effects, and personal weight loss goals rather than trial averages alone.
Side Effects and Tolerability: What to Expect
Nausea, vomiting, diarrhea, and constipation occur with both medications, typically during dose escalation phases. Most patients report side effects diminish as their body adapts over 4–8 weeks, though individual tolerance varies significantly. Starting with lower doses and advancing gradually minimizes gastrointestinal disruption.
Tirzepatide carries a slightly higher incidence of nausea compared to semaglutide in clinical trials, though serious adverse events remain rare with proper medical supervision. Both medications carry a black-box warning for thyroid C-cell tumors based on animal studies; human risk remains theoretical and unproven.
Dehydration risk, pancreatitis history, and personal medication sensitivities should guide your choice. PlexusDx providers assess your complete medical profile to recommend the medication most likely to deliver benefit with manageable side effects for your unique situation.
Personalized Selection: Genetic Testing and Your Best Option
Not every patient responds identically to tirzepatide or semaglutide. Your genetic variants in the GLP1R gene (rs6923761), GIPR gene (rs1800437), and metabolic regulators like MC4R and FTO influence how effectively each medication works for your body's specific peptide pathways.
PlexusDx Precision Peptide Genetic Test analyzes 14 metabolic pathways, 49 peptides, and 150+ genetic insights to map your individual response potential to GLP-1 and GIP receptor therapy. This $99 add-on after your first month of treatment identifies whether tirzepatide's dual-pathway approach aligns with your genetic predispositions or if semaglutide's focused GLP-1 activation better suits your biology.
Genetic testing transforms weight loss from one-size-fits-all guessing into precision medicine. PlexusDx offers both compounded tirzepatide and semaglutide injections (from licensed 503A pharmacies, starting at $289/mo and $189/mo respectively) so you access the medication that fits your genetic profile and budget.
Cost, Access, and Treatment Flexibility with PlexusDx
PlexusDx compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan) with no insurance required, no membership fees, and HSA/FSA eligibility. Your dose may need to go up. Your price won't. This flat-rate model removes financial barriers to dose adjustments that optimize your weight loss response.
Semaglutide injection from PlexusDx begins at $189/mo (or $149/mo on the 6-month plan) for patients preferring single-receptor activation or seeking a lower-cost entry point. Both medications are compounded by licensed 503A pharmacies serving all 50 states, offering quality assurance and state-level oversight that distinguishes compounded therapy from unregulated alternatives.
If you remain uncertain between tirzepatide and semaglutide, PlexusDx GLP-Squared Injection (starting at $289/mo (or $249/mo on the 3-month plan)) combines both compounds in microdose protocols for patients exploring dual-pathway therapy without full tirzepatide doses. Oral formulations of all medications are also available for those preferring non-injection routes.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Which medication causes more weight loss: Mounjaro or Ozempic?
Tirzepatide (Mounjaro) produced 21–22% average weight loss in clinical trials versus semaglutide's 14–17%, but individual results vary widely. Your genetic makeup, starting weight, metabolism, and adherence matter more than trial averages. PlexusDx Precision Peptide Genetic Testing identifies which medication aligns with your unique peptide pathways.
Is tirzepatide safer than semaglutide?
Both medications carry similar safety profiles when prescribed under medical supervision. Tirzepatide shows slightly higher nausea rates; semaglutide has longer real-world safety data. Serious adverse events remain rare with both. PlexusDx providers review your medical history to recommend the safest option for your specific health circumstances.
Can I switch between Mounjaro and Ozempic if one doesn't work?
Yes. If you don't achieve desired results or experience intolerable side effects with one medication, switching to the other is medically appropriate. PlexusDx supports medication transitions and can provide compounded semaglutide or tirzepatide depending on your provider's recommendation and your treatment response.
How much does tirzepatide cost with PlexusDx compared to brand Mounjaro?
PlexusDx compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan) with no insurance required. Brand Mounjaro typically costs $1,000+ monthly without insurance. Your dose may increase during treatment, but PlexusDx pricing remains flat across all dose levels, making sustainable therapy affordable.
How does genetic testing help me choose between these medications?
PlexusDx Precision Peptide Genetic Test ($99 add-on) analyzes your GLP1R, GIPR, MC4R, and FTO variants, revealing which medication's mechanism aligns with your genetic predispositions. Testing transforms guesswork into precision medicine, helping your provider select tirzepatide's dual-pathway approach or semaglutide's single-receptor focus based on your biology.
Are compounded versions of these medications as effective as brand names?
PlexusDx tirzepatide and semaglutide are compounded by licensed 503A pharmacies under strict pharmaceutical regulations. Compounded medications contain identical active ingredients to brands; differences lie in cost, accessibility, and personalization. Studies show equivalent efficacy when formulated to pharmaceutical standards.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Understanding Nausea Duration with Zepbound: What to Expect and How to Manage It
How Often Do You Need to Inject Wegovy?